xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

339

ICAR SINONASAL TUMORS

TABLE XXX.1 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Concurrent use of multiple instruments may better discern QOL outcomes after endoscopic tumor surgery

Evaluate

Deckard

2015 3

Prospective cohort

Patients with sinonasal and skull base tumors ( n = 71) ∙ Benign tumors (IP,

et al. 2085

postoperative QOLafter endoscopic resection of

JNA, pituitary adenoma, and others) ( n = 39) Malignant tumors (SCC,ONB,

sinus and skull base neoplasms using

validated outcomes measures (SNOT-20, ASBQ, EQ-5D, andLKE scores) and perform correlation of the various metrics

adenocarcinoma, ACC, and others) ( n = 32)

Amit et al. 2069

2012 3

Systematic

Patients undergoing endoscopic or open extirpation of anterior skull base tumors, benign or malignant ( n = 118) evaluated withASBQ ∙ Retrospective evaluation ( n = 79) Prospective evaluation ( n = 39) Patients who underwent endoscopic or open approach for ∙ An anterior or central skull base pathology ( n = 138) ∙ Endoscopic/anterior ( n = 17;ONB, meningioma, encephalocele) ∙ Endoscopic/central ( n = 48; pituitary adenoma, chordoma, craniopharyngioma) ( n = 48; ONB, SCC, hemangiopericy toma, adenocystic) ( n = 25, chordoma, chondrosarcoma, craniopharyngioma) ∙ Open/anterior ∙ open/central

Determine the clinical

The MCID of the ASBQ was 0.4

reviewand meta analysis of retrospective case series

significance of ASBQ scores

1. 41 questions with 11

Systematic reviewto identify

deAlmeida et al. 2070

2012 3

Retrospective

disease-specific domains SBI was developed 2. No reliability, validity and responsiveness testing done

cohort study with devel opment of instrument

relevant QOL instruments and develop a disease specific QOL questionnaire for anterior and central

skull base pathology

(Continues)